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Background/aim: Overt thyroidism is known to cause neuropsychiatric disorders but studies on subclinical hyperthyroidism (SCH) are
limited. Subclinical hyperthyroidism induction by administering L-Thyroxine (LT4) is the standard treatment method in differentiated
thyroid carcinoma (DTC) follow-up. Our aim was to investigate whether anxiety, depression and quality of life are affected in DTC
patients followed-up with exogenous SCH.
Materials and methods: The patients were divided into exogenous SCH by LT4-DTC (n = 127), euthyroid-DTC (n = 66) and exogenous
euthyroid-benign thyroid noduüle (BTN) who underwent thyroidectomy for benign thyroid pathology (n = 85) groups.
Results: The rate of moderate/severe anxiety was significantly higher in SCH-DTC than euthyroid-BTN group (27.5%, n = 35 vs. 9.4%, n
= 8) (P = 0.001). TSH levels and Beck anxiety inventory (BAI) scores were significantly negatively correlated(P = 0.009 r = –0.16). Free
T4 and BAI were significantly positively correlated (P = 0.04 r = 0.4). The groups were similar in terms of depression severity (P = 0.15).
Subclinical hyperthyroid-DTC group scored significantly lowerthan euthyroid-BTN group in all scales of SF-36 quality of life survey.
Conclusion: LT4-induced SCH, which is a part of traditional DTC treatment, can exacerbate the anxiety symptoms in patients and
disrupt their quality of life, depending on the level of fT4.
Keywords: Beck anxiety and depression inventory, differentiated thyroid carcinoma, SF-36 quality of life survey, subclinical
hyperthyroidism, TSH suppression

1. Introduction
Differentiated thyroid carcinoma is the most common type
of endocrinological neoplasm [1]. The disease has a general
mortality rate of less than 10%, and most patients have a
long survival due to the tumour’s biological behaviour and
treatment’s efficacy [2]. Conventional treatment for DTC
includes total or partial thyroidectomy, remnant tissue
radioactive iodine (RAI) ablation, and thyroid stimulating
hormone/thyrotropin (TSH) suppression with LT4.
The latter serves to create an exogenous SCH (a normal
serum free T3 (fT3) free T4 (fT4) but with a reduced TSH
concentration) [3]. These chemical changes are associated
with increased cardiovascular risk, fatigue, reduced bone
mineral density, and impaired muscle function [4–7]. Such
changes may affect patients’ physical and psychological
status and impair their quality of life (QoL) [7,8] and they
may also be associated with depression [9,10] and anxiety
[11,12]. Affect and anxiety disorders are more common
among patients with thyroid disorders [13]. Patients with

DTC may suffer SCH symptoms, which may impair QoL
[14,15]. The aim of the present study is to investigate
the effects of exogenous SCH during the follow-up of
differentiated thyroid cancers on patients’ QoL and
symptoms of anxiety-depression.
2. Materials and methods
2.1. Study population
A total of 278 patients who underwent thyroid surgery
and admitted to Başkent University Ankara Hospital,
Endocrinology outpatient clinic between 01/2015–
01/2016 were included in the study. The patients were
divided into exogenous SCH by LT4-DTC (n = 127),
euthyroid-DTC (n = 66) and exogenous euthyroidBTN who underwent thyroidectomy for benign thyroid
pathology (n = 85) groups. SF-36 quality of life survey and
Beck anxiety-depression inventory were performed on
patients. Patients aged 18 years or above, who are educated
enough to appropriately fill the self-evaluation form on
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their own, with no previous history of psychiatric disorder
or substance abuse were included in the study. Free T3,
fT4 and TSH levels were measured and recorded from the
patients’ fasting blood samples, before the administration
of LT4. Serum TSH (0.48–4.94 mU/L), fT4 (0.7–1.48 ng/
dL), fT3 (1.71–3.71 ng/L) levels were measured using
electro-chemiluminescence
immunoassay
(ECLIA)
method. Subclinical hyperthyroidism was defined as
having serum TSH levels below the reference range, and
fT3 and fT4 levels within the reference range [2].
2.2. Instruments
2.2.1. Beck depression inventory (BDI)/Beck anxiety
inventory (BAI)
This inventory is a self-assessment scale for rating a patient’s
level and severity of depression/anxiety. It aims to rate the
severity of depressive symptoms. It consists of 21 items,
each of which is scored between 0–3 points. A high total
point indicates a more severe depression/anxiety. A score
of 0–13 is considered normal; 14–19 points indicate mild
depression; 20–28 points indicate moderate depression,
and 29–63 points indicate severe depression [16]. As
for BAI; 0–7 points are considered normal; 8–15 points
indicate mild anxiety; 16–25 points indicate moderate
anxiety; and 26–63 points indicate severe anxiety [17].
The reliability and validity of the Turkish versions of these
instruments have been examined [18,19].
2.2.2. Health survey short form-36 (SF-36)
The SF-36 is used to assess QoL [20]. This instrument
is a 36-item self-report questionnaire with eight scales
measuring major domains of functional health and wellbeing, role limitations due to physical problems, body
pain, general health, vitality, social functioning, role
limitations due to emotional problems and mental health.
Each scale provides a score ranging from 0 to 100, with
higher scores indicating better health status. The validity
and reliability of the Turkish versions of SF-36 have been
extensively documented [21].
2.3. Data analysis
For this study’s power analysis, G-power 3.1 softwares were
used. In the study, 3 independent groups were compared.
Power test F test ANOVA one-way was used. In the study,
effect size 0.24 Type 1 error was taken 0.05 and the power
of the study is 95%. All data analyses were performed with
SPSS software (Statistical Package for the Social Sciences,
version 15.0). Normality distribution analysis of the
data was performed by using Kolmogorov-Smirnov and
Shapiro-Wilk tests. One-way ANOVA analysis of variance
and Tukey’s multiple comparison posthoc tests were used
for comparison of qualitative variables among groups.
The differences between independent groups in terms of
numerical variables were examined using the Student’s ttest to compare means. Chi-square (χ2) test was used to

analyze categorical variables. Pearson’s tests were used
to test correlations and the degree of associations among
variables. A P-value of < 0.05 was considered statistically
significant.
3. Results
The groups were similar in terms of the mean age and
sex distribution of patients (P = 0.68 P = 0.3). Free T4
level was significantly higher in SCH-DTC group than
euthyroid-BTN group (P = 0.002), and was similar to the
level in euthyroid-DTC group (P = 0.17) (Table 1).
When groups were compared in terms of BDI, it was
found that 72.4% (n = 92) of the patients in SCH-DTC
group were normal, whereas 16.5% (n = 21) had mild,
8.7% (n = 11) had moderate, and 2.4% (n = 3) had severe
depression. In euthyroid-DTC group, 83.3% (n = 55) of
the patients were normal, whereas 9.1% (n = 6) had mild,
6.1% (n = 4) had moderate, and 1.5% (n = 1) had severe
depression. In euthyroid-BTN group, 87.1% (n = 74) of
the patients were normal, and 10.6% (n = 9) had mild,
1.2% (n = 1) had moderate, and 1.2% (n = 1) had severe
depression, and the groups were similar in terms of rates
of depression severity (P = 0.15) (Table 2). When groups
were compared in terms of BAI, it was found that 32.3% (n
= 41) of the patients in SCH-DTC were normal, whereas
40.2% (n = 51) had mild, 15.7% (n = 20) had moderate,
and 11.8% (n = 15) had severe anxiety. In euthyroid-DTC
group, 57.6% (n = 38) of the patients were normal, and
24.2% (n = 16) had mild, 13.6% (n = 9) had moderate and
4.5% (n = 3) had severe anxiety. In euthyroid-BTN group,
48.2% (n = 41) of the patients were normal, and 42.4% (n
= 36) had mild, 9.4% (n = 8) had moderate anxiety and
severe anxiety was not detected in any of the patients.
The rate of moderate/severe anxiety in SCH-DTC group
was 27.5% (n = 35), which was significantly higher than
euthyroid-BTN group with 9.4% (n = 8) (P = 0.001) (Table
2).
In terms of SF-36 quality of life survey, SCH- DTC
group scored lower than euthyroid-BTN group in all scales
of the survey (physical functioning, role limitation due
to physical problems, body pain, general health, vitality,
social functioning, role limitation due to emotional
problems, mental health) (P < 0.001, P = 0.03, P = 0.002, P
< 0.001, P < 0.001, P < 0.001, P < 0.001, P < 0.001). Vitality
and mental health scores were significantly lower in SCHDTC group than euthyroid-DTC group (P = 0.007, P =
0.03, respectively) (Table 3).
In the correlation analysis, no significant correlation
was detected between TSH levels and BDI scores (P =
0.073 r = –0.1) . A significant negative correlation was
detected between TSH levels and BAI scores (P = 0.009 r =
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Table 1. General characteristics of the study groups.
Characteristics

SCH-DTC
n = 127

Euthyroid-DTC
n = 66

Euthyroid-BTN
n = 85

P

Age ± SD

51.92 ± 11.82

51.62 ± 14.06

50.1 ± 12.17

0.68

Female n (%)

106 (83.5)

53 (80.3)

61 (71.8)

Male n (%)

21 (16.5)

13 (19.7)

24 (28.2)

TSH mU/L± SD

0.12 ± 0.12

1.14 ± 0.73

fT3 ng/L± SD

3.1 ± 0.26

2.8 ± 0.35

fT4 ng/dL ± SD

1.33 ± 0.22

1.24 ± 0.14

P*

P**

P***

1.9 ± 1.27

<0.001

<0.001

<0.001

2.87 ± 0.35

0.051

0.13

0.66

1.12 ± 0.13

0.17

0.002

0.06

Sex

0.3

DTC: Differentiated thyroid cancer, BTN: Benign thyroid nodule, fT3: Free triiodothyronine, fT4: Free thyroxine, SCH:
Subclinical hyperthyroidism, TSH: Thyroid stimulating hormone, SD: Standard deviation, P: Difference between all
groups, P*: Difference between SCH-DTC and euthyroid-DTC, P**: Difference between SCH-DTC and euthyroid-BTN,
P***: Difference between euthyroid-DTC and euthyroid-BTN, P-value <0.05 was considered statistically significant, Age P:
Difference between SCH-DTC, euthyroid-DTC and euthyroid-BTN (ANOVA test), Sex P: Difference between SCH-DTC,
euthyroid-DTC and euthyroid-BTN (Chi-square test), p* p** p*** : Student’s t- test.
Table 2. Comparison of groups in terms of Beck depression and anxiety scores.
SCH-DTC
n = 127

Euthyroid-DTC
n = 66

Euthyroid-BTN
n = 85

Beck depression score

P

P*

P**

P***

0.15

Normal (0–13) n (%)

92 (72.4)

55 (83.3)

74 (87.1)

Mild (14–19) n (%)

21 (16.5)

6 (9.1)

9 (10.6)

Moderate (20–28) n (%)

11 (8.7)

4 (6.1)

1 (1.2)

Severe (29–63) n (%)

3 (2.4)

1 (1.5)

1 (1.2)

Normal (0–7) n (%)

41 (32.3)

38 (57.6)

41 (48.2)

0.002

0.001

0.01

0.25

Mild (8–15) n (%)

51 (40.2)

16 (24.2)

36 (42.4)

0.03

0.028

0.75

0.02

Moderate (16–25) n (%)

20 (15.7)

9 (13.6)

8 (9.4)

0.41

Severe (26–63) n (%)

15 (11.8)

3 (4.5)

0 (0)

0.002

0.1

0.001

0.08

Moderate + Severe n (%)

35 (27.5)

12 (18.1)

8 (9.4)

0.005

0.15

0.001

0.11

Beck anxiety score

0.001

DTC: Differentiated thyroid cancer, BTN: Benign thyroid nodule, SCH: Subclinical hyperthyroidism, P: Difference between SCHDTC, euthyroid-DTC and euthyroid- BTN (Chi-square test), P*: Difference between SCH-DTC and euthyroid-DTC, P**: Difference
between SCH-DTC and euthyroid-BTN, P***: Difference between euthyroid-DTC and euthyroid- BTN, P-value <0.05 was considered
statistically significant.

–0.16). In terms of SF-36 quality of life survey, a statistically
significant weak positive correlation was detected between
TSH and physical functioning, body pain, general health,
vitality, social functioning and mental health scales (P =
0.015 r = 0.14, P = 0.006 r= 0.16, P = 0.002 r = 0.18,
P = 0.001 r =0.2, P = 0.01 r = 0.15, P = 0.001 r = 0.2,
respectively). No correlation was detected between role
limitation due to physical and emotional problems scales
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and TSH (P = 0.2 r = 0.07, P = 0.1 r = 0.1, respectively). A
significant negative correlation was detected between fT4
and vitality, social functioning and mental health scales
of SF-36 quality of life survey (P = 0.027 r = –0.42, P =
0.04 r = –0.4, P = 0.01 r = –0.48). A significant positive
correlation was detected between fT4 and BAI (P = 0.04
r =0.4). There was no significant correlation between fT3
and SF36, BDI and BAI socres (Table 4).
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Table 3. Comparison of groups in terms of SF-36 scale scores.
SCH-DTC
n = 127

Euthyroid-DTC
n = 66

Euthyroid-BTN
n = 85

P

P*

P**

P***

Physical functioning

73.54 ± 22.98

81.97 ± 44.96

83 ± 15.85

0.02

0.08

<0.001

0.17

Role- physical

71.65 ± 52.55

74.62 ± 37.09

82.94 ± 25.64

0.04

0.68

0.03

0.37

Body pain

67.87 ± 22.87

73.33 ± 20.48

76.7 ± 18.4

0.02

0.1

0.002

0.3

General health

54.88 ± 19.55

60.53 ± 20.96

66.23 ± 15.48

<0.001

0.65

<0.001

0.12

55.11 ± 18.79

62.57 ± 22.70

70 ± 15.1

<0.001

0.007

<0.001

0.052

Social functioning

72.05 ± 21.67

75.56 ± 22.19

86.4 ± 15.81

<0.001

0.29

<0.001

0.001

Role-emotional

60.62 ± 64.16

68.18 ± 41.52

86.66 ± 22.53

<0.001

0.38

<0.001

0.035

Mental health

60.03 ± 17.4

65.94 ± 19.16

71.76 ± 13.21

<0.001

0.03

<0.001

0.085

SF-36 scale (mean ± SD)

Vitality

DTC: Differentiated thyroid cancer, BTN: Benign thyroid nodule, SCH: Subclinical hyperthyroidism, SD: Standard deviation, P:
Difference between SCH-DTC, euthyroid-DTC and euthyroid-BTN (ANOVA test), P*: Difference between SCH-DTC and euthyroidDTC, P**: Difference between SCH-DTC and euthyroid- BTN, P***: Difference between euthyroid-DTC and euthyroid-BTN, P-value
<0.05 was considered statistically significant, P* P** P*** : Student’s t- test.

Table 4. Correlation between thyroid function tests and SF-36, BDI and BAI scales.
TSH
r

P

fT4
r

P

fT3
r

P

Physical functioning

0.14

0.015

–0.08

0.69

0.2

0.31

Role- physical

0.07

0.2

–0.08

0.68

0.05

0.8

Body pain

0.16

0.006

0.19

0.35

0.27

0.16

General health

0.18

0.002

–0.01

0.95

–0.21

0.27

Vitality

0.2

0.001

–0.42

0.027

–0.01

0.95

Social functioning

0.15

0.01

–0.4

0.04

–0.11

0.57

Role-emotional

0.1

0.1

–0.3

0.13

–0.26

0.18

Mental health

0.2

0.001

–0.48

0.01

–0.2

0.34

BDI

–0.1

0.07

0.3

0.11

0.1

0.6

BAI

–0.16

0.009

0.4

0.04

0.2

0.31

SF-36

BAI: Beck anxiety inventory, BDI: Beck depression inventory, fT3: Free triiodothyronine,
fT4: Free thyroxine, SCH: Subclinical hyperthyroidism, TSH: Thyroid stimulating
hormone, P-value <0.05 was considered statistically significant.

4. Discussion
In our study, SCH-DTC group scored lower than
euthyroid-BTN in most of the SF-36 QoL scores and
lower than euthyroid-DTC in some of the SF-36 QoL
scores. Among all malignancies, DTC has one of the
highest remission rates and is associated with a high
long-term survival rate [2]. The conventional treatment
of DTC involves LT4 replacement and TSH suppression

to minimize disease recurrence. However, the resulting
subclinical hypothyroidism is associated with physical
and psychological abnormalities that may adversely affect
QoL [4,7]. In some cancer patients, being aware of the
cancer diagnosis may also negatively affect their quality
of life [22]. Therefore, diagnosing additional pathological
conditions further impairing patients’ quality of life may
benefit survival. Vigario et al. reported that patients with
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SCH-DTC undergoing LT4 suppression treatment had
a worse quality of life compared to those with euthyroid
DTC [23]. Similarly, De Oliveira Chachamovitz et al.
compared 38 patients with SCH-DTC and 54 patients with
euthyroid DTC, and showed that patients with SCH-DTC
had a lower quality of life than patients with euthyroid DTC
[7]. In these studies, fT4 levels in patients with SCH were
significantly higher than the euthyroid group. In our study,
since there were no difference between SCH-DTC and
euthyroid-DTC groups in terms of fT4 levels, most of their
quality of life scale scores were similar. Moreover, since fT4
level in SCH-DTC group was higher than euthyroid-BTN
group, most of the quality of life scale scores were lower.
It appears that quality of life is essentially affected by fT4
levels.
Thyroid dysfunction is known to cause significant
mental symptoms and depression anxiety disorders are
more common among patients with thyroid disorders [13].
Subclinical hyperthyroidism may cause affect disorders
[24]. Panic attack and generalized anxiety are common
disorders in thyroid dysfunction, particularly in overt
hyperthyroidism [13,25–28]. However, data on whether
SCH increases anxiety are limited and contradictory
[29,30]. Thyroid hormones affect neuropsychiatric
condition by increasing the activity of catecholamines.
Studies have shown that thyroid hormones increases the
number and activity of beta-catecholamine receptors
[31,32]. Sait Gönen et al. reported significantly higher
anxiety scoresand fT4 levels in patients with SCH
compared to an euthyroid population [11]. Correlation
analysis of our study showed a weak albeit significant
correlation between TSH and fT4 levels and BAI scores.
We found a significantly higher rate of moderate/severe
anxiety in the SCH group (27.5%) than euthyroid-BTN.
Here, the determining factor is the difference between fT4
levels. Subclinical hypothyroid-DTC and euthyroid-DTC
groups, which had similar fT4 levels, were also similar
in terms of anxiety severity. It was reported that even a
minimal change in thyroid hormones can have behavioral
effects [33]. Based on these data, it can be said that anxiety
severity is affected by fT4 levels in SCH.
There is a small body of prospective data on the
impact of SCH on depression [13]. Furthermore, studies
with large patient series have yielded conflicting results
[10,34]. In a 1219-patient study, Renate et al. concluded
that patients with SCH had similar physical, cognitive
functions and depression symptoms as euthyroid patients
[34]. In a study of 1503 patients by Medici M et al., those
with SCH had higher depressive symptom scores, and a
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prospective evaluation revealed that low TSH levels were
associated with an increased incidence of depression
[10]. The 3-year outcomes of another study showed that
patients with SCH had higher depression scores than
euthyroid ones [9]. Eustatia-Rutten et al. studied patients
with DTC undergoing TSH suppression and showed that
exogenously induced SCH was associated with higher
depression scores than the euthyroid healthy control
group [35]. Our study revealed similar rates of severe
depression among SCH and control groups. TSH and BDI
scores were not correlated. These differences may be due
to the absence of the inclusion of multiple other factors
affecting the results.
In conclusion; TSH suppression therapy administered
for differentiated thyroid cancers are associated with
significantly increased anxiety symptom scores but not
depression scores. Most parameters of the QoL rating scale
were negatively affected by TSH suppression. According to
our findings, fT4 levels are correlated with anxiety in SCHDTC, and it may have therefore caused disruption in the
quality of life. It must be kept in mind that SCH induced
by TSH suppression in patients with DTC can disrupt the
patients’ psychological status and quality of life.
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